Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Precision Medicine in Hormone Receptor-Positive Breast Cancer.
Nasrazadani A, Thomas RA, Oesterreich S, Lee AV. Nasrazadani A, et al. Front Oncol. 2018 May 4;8:144. doi: 10.3389/fonc.2018.00144. eCollection 2018. Front Oncol. 2018. PMID: 29780747 Free PMC article. Review.
Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.
Chen P, O'Neal JF, Ebelt ND, Cantrell MA, Mitra S, Nasrazadani A, Vandenbroek TL, Heasley LE, Van Den Berg CL. Chen P, et al. Among authors: nasrazadani a. PLoS One. 2010 May 3;5(5):e10443. doi: 10.1371/journal.pone.0010443. PLoS One. 2010. PMID: 20454618 Free PMC article.
c-Jun N-terminal Kinase 2 Regulates Multiple Receptor Tyrosine Kinase Pathways in Mouse Mammary Tumor Growth and Metastasis.
Nasrazadani A, Van Den Berg CL. Nasrazadani A, et al. Genes Cancer. 2011 Jan;2(1):31-45. doi: 10.1177/1947601911400901. Genes Cancer. 2011. PMID: 21779479 Free PMC article.
The Evolving Landscape of HER2-Directed Breast Cancer Therapy.
Marti JLG, Hyder T, Nasrazadani A, Brufsky AM. Marti JLG, et al. Among authors: nasrazadani a. Curr Treat Options Oncol. 2020 Aug 7;21(10):82. doi: 10.1007/s11864-020-00780-6. Curr Treat Options Oncol. 2020. PMID: 32767149 Review.
Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.
Brufsky A, Marti JLG, Nasrazadani A, Lotze MT. Brufsky A, et al. Among authors: nasrazadani a. J Transl Med. 2020 Jun 29;18(1):261. doi: 10.1186/s12967-020-02433-6. J Transl Med. 2020. PMID: 32600410 Free PMC article. Review.
Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
Nasrazadani A, Brufsky A. Nasrazadani A, et al. Future Oncol. 2020 Mar;16(7):247-254. doi: 10.2217/fon-2019-0719. Epub 2020 Feb 14. Future Oncol. 2020. PMID: 32057254 Free article. Review.
Capivasertib inhibits a key pathway in metastatic breast cancer.
Nasrazadani A, Brufsky AM. Nasrazadani A, et al. Lancet Oncol. 2020 Mar;21(3):318-319. doi: 10.1016/S1470-2045(19)30857-5. Epub 2020 Feb 5. Lancet Oncol. 2020. PMID: 32035019 Free article. No abstract available.
CDK4/6 inhibitors: taking the place of chemotherapy?
Nasrazadani A, Brufsky AM. Nasrazadani A, et al. Lancet Oncol. 2019 Oct;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. Epub 2019 Sep 4. Lancet Oncol. 2019. PMID: 31494036 No abstract available.
Artificial intelligence-directed prognostication of breast cancer.
Nasrazadani A, Brufsky AM. Nasrazadani A, et al. EBioMedicine. 2019 Aug;46:6-7. doi: 10.1016/j.ebiom.2019.07.073. Epub 2019 Aug 1. EBioMedicine. 2019. PMID: 31378696 Free PMC article. No abstract available.
Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma.
Amaya CN, Perkins M, Belmont A, Herrera C, Nasrazadani A, Vargas A, Khayou T, Montoya A, Ballou Y, Galvan D, Rivas A, Rains S, Patel L, Ortega V, Lopez C, Chow W, Dickerson EB, Bryan BA. Amaya CN, et al. Among authors: nasrazadani a. Oncoscience. 2018 Apr 29;5(3-4):109-119. doi: 10.18632/oncoscience.413. eCollection 2018 Mar. Oncoscience. 2018. PMID: 29854879 Free PMC article.
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page